News

News Subscription

Jan 13. 2022
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
Read more
Download
Jan 11. 2022
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
Read more
Download
Jan 10. 2022 / Ad hoc announcement
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
Read more
Download
Jan 07. 2022 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
Read more
Download
Jan 06. 2022
Basilea reports on portfolio progress made in 2021
Read more
Download
Dec 21. 2021 / Ad hoc announcement
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China
Read more
Download
Dec 17. 2021 / Ad hoc announcement
Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891
Read more
Download
Dec 08. 2021 / Ad hoc announcement
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
Read more
Download
Nov 16. 2021
Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891
Read more
Download
Oct 11. 2021
Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference
Read more
Download